Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial

Bleeding Clinical Trial

Official title:

Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01873898
• Other study ID #: REX-OUS-2027-004
• Status: Completed
• Phase: N/A
• First received: June 6, 2013
• Last updated: September 26, 2017
• Start date: June 2013
• Est. completion date: July 2013

Study information

• Verified date: September 2017
• Source: Rex Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the Rex Medical Closer™ Vascular Closure System to close the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures with early ambulation and discharge.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is > 18 years of age.

• Subject is able to undergo diagnostic angiography procedure and is found suitable to receive such a device at the femoral arterial puncture site in order to reduce time to hemostasis.

• Subject or his/her legal guardian understands the nature of the procedure, and provides written informed consent prior to the procedure.

• Subject is available and willing to participate in follow-up through 30 days post femoral closure.

Exclusion Criteria:

• Subject with known allergies to polylactic acid (PLA), polyglycolic acid (PGA) or polydioxanone (PDO) polymers

• Subject with severe acute non-cardiac systemic disease

• Subject with evidence of systemic infection

• Subject where bacterial contamination of the procedural sheath or surrounding tissues may have occurred as this may increase risk of infection

• Subject with coagulopathy (bleeding disorders, including thrombocytopenia, hemophilia, etc.)

• Subject taking thrombolytic medication which reduces fibrinogen to less than 100 mg/dl

• Subject who has had a previous arterial access in the femoral artery on the treatment side with an existing hematoma >5 cm in diameter

• Subject who is unable to ambulate at baseline

• Subject who has had another closure device used in the treatment side within the previous 90 days

• Subject who requires re-entry of the treatment side planned within the next 90 days post-procedure

• Subject has a history of surgical repair on the treatment side

• Subject has planned surgeries for any reason within 90 days post- procedure

• Subject is pregnant or is lactating (non-pregnancy must be confirmed by testing)

• Has a history of a psychiatric condition, substance abuse or alcohol abuse that, in the opinion of the investigator, will potentially interfere with his or her participation

• Subject has been previously enrolled in the Rex Closer™ study

• Subject who is currently or within the previous 4 weeks been enrolled in another investigational device or drug trial

• Subject is incarcerated at the time of enrollment

• Subject where the procedural sheath has been placed through the superficial femoral artery and into the profundafemoris

• Subject where the procedure puncture site is at or distal to the bifurcation of the superficial femoral profundafemoris artery, as this may result in 1) the intravascular sealing patch catching on the bifurcation or being positioned incorrectly, and/or 2) intravascular deployment of the device into the vessel (These events may reduce blood flow through the vessel leading to symptoms of distal arterial insufficiency.)

• Subject's procedure was accessed through a vascular graft

• Subjects with uncontrolled hypertension (> 230 mm Hg systolic)

• Subjects with small femoral artery size (Less than 5 mm in diameter)

• Subjects with stenosis > 50% at the vicinity of the femoral arterial puncture site

• Subjects with anomalous branches or vessel abnormalities present in the vicinity of the femoral arterial puncture site

Related Conditions & MeSH terms

• Bleeding

Intervention

Device:
• Rex Medical Closer™ Vascular Closure System
The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.

Locations

Country	Name	City	State
Paraguay	Centro de IntervencionesEndovasculares Y Cirugia Cardiovascular	Asuncion

Sponsors (1)

Lead Sponsor	Collaborator
Rex Medical

Country where clinical trial is conducted

Paraguay, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Ambulation	Time to Ambulation - in minutes, defined as the time from when hemostasis is achieved to the time when ambulation is achieved (patient standing and walking at least 6.1 meters [20 feet] without re-bleeding).	Day 0
Primary	Frequency of Major Adverse Events through 30 days	The primary safety endpoint is the frequency of Major Adverse Events through 30 days, defined as one of the following events related to the use of the investigational device: a hematoma requiring a transfusion, a device embolization, false aneurysm requiring intervention or a retroperitoneal bleed.	30 days
Secondary	Time to Hemostasis	Time to Hemostasis - in minutes, defined as the time from when the delivery system releases both sutures, which are attached to the sealing member, to the time that hemostasis (absence of expanding or developing hematoma) is achieved	Day 0
Secondary	Placement Technical Success	Placement Technical Success - defined as the successful deployment of the device at the intended placement site such that hemostasis is achieved.	Day 0
Secondary	Clinical Success	Clinical Success - evaluated from the time of device deployment, and defined as Placement Technical Success in the absence of any major safety endpoint including subsequent hematoma requiring a transfusion, a device embolization, false aneurysm requiring intervention, or retroperitoneal bleeding.	Day 0